Elahere Combination Achieves 62.7% ORR in Phase 2 Trial for Platinum-Sensitive Ovarian Cancer at SGO 2026

Why It Matters

The high ORR and sustained activity, even after PARP‑inhibitor exposure, position the Elahere‑carboplatin regimen as a promising new option for recurrent platinum‑sensitive ovarian cancer, potentially extending survival and delaying more toxic therapies. This data supports advancing ADC‑based combinations into later‑stage trials and could reshape standard of care for FRα‑expressing tumors.

Key Takeaways

• Elahere + carboplatin achieved 62.7% ORR in FRα‑positive PSOC
• Response maintained; ORR rose to 68% during monotherapy continuation
• 49% of patients had prior PARP inhibitor exposure, still showed 63.9% ORR
• Grade ≥3 neutropenia occurred in 15%; ocular adverse events were most common

Pulse Analysis

Ovarian cancer remains the deadliest gynecologic malignancy, with recurrence after platinum therapy driving most mortality. The emergence of antibody‑drug conjugates (ADCs) targeting folate receptor alpha (FRα) offers a biologically rational approach, leveraging tumor‑specific expression to deliver cytotoxic payloads while sparing normal tissue. Elahere, AbbVie’s first‑in‑class FRα‑directed ADC, received full FDA approval in 2024 for platinum‑resistant disease, setting the stage for combination strategies that could broaden its utility across the treatment continuum.

The Phase 2 IMGN853‑0420 trial presented at SGO 2026 provides compelling evidence that pairing Elahere with carboplatin yields a 62.7% objective response rate in patients whose tumors express ≥50% FRα, surpassing historical benchmarks for second‑line platinum‑sensitive regimens. Notably, the benefit persisted in the 49% of participants previously treated with PARP inhibitors, a cohort traditionally considered less responsive to further platinum. Median response duration of 11.2 months and an increased 68% ORR during the maintenance monotherapy phase suggest durable disease control, while the safety profile—dominated by manageable ocular events and 15% grade 3/4 neutropenia—remains consistent with prior monotherapy data.

From a market perspective, these findings could accelerate the integration of ADC‑based combinations into standard ovarian cancer algorithms, challenging the dominance of traditional chemotherapy and PARP inhibitor sequences. If subsequent Phase 3 trials confirm efficacy and safety, Elahere‑carboplatin may capture a sizable share of the recurrent platinum‑sensitive segment, driving incremental revenue for AbbVie and prompting competitors to explore similar FRα‑targeted constructs. Moreover, the data reinforces the strategic value of biomarker‑driven trials, encouraging broader adoption of FRα testing to identify patients most likely to benefit.